Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-saharan africa

Clinical and Vaccine Immunology

Volumn 16, Issue 4, 2009, Pages 479-483

  Tejiokem, Mathurin C ^a   Njamkepo, Elisabeth ^f   Gouandjika, Ionela ^g   Rousset, Dominique ^b   Beniguel, Lydie ^g   Bilong, Catherine ^c   Tene, Gilbert ^d   Penda, Ida ^e   Ngongueu, Carine ^h   Gody, Jean C ^g   Guiso, Nicole ^b   Baril, Laurence ⁱ  

^a Laboratoire d'Épidémiologie et de Santé Publique   (Cameroon)

^b Laboratoire de Virologie   (France)

^c CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^d Mother and Child Centre of The Chantal Biya Foundation Yaounde   (Cameroon)

^e Hopital Laquintinie   (Cameroon)

^f INSTITUT PASTEUR   (France)

^g INSTITUT PASTEUR DE BANGUI   (Central African Republic)

^h Laboratoire des Rétrovirus   (Central African Republic)

ⁱ INSTITUT PASTEUR DE DAKAR   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ANTIBODY; ANTIRETROVIRUS AGENT; DIPHTHERIA TETANUS VACCINE; PERTUSSIS VACCINE;

AFRICA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CAMEROON; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNIZATION; LIFE EXPECTANCY; MALE; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ANTIBODIES, BACTERIAL; CAMEROON; CENTRAL AFRICAN REPUBLIC; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HIV INFECTIONS; HUMANS; INFANT;

EID: 64549093305     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00312-08     Document Type: Article

References (23)

1. Adamson, P. C., T. C. Wu, B. D. Meade, M. Rubin, C. R. Manclark, and P. A. Pizzo. 1989. Pertussis in a previously immunized child with human immunodeficiency virus infection. J. Pediatr. 115:589-592.
2. Anonymous. 2005. Pertussis vaccines-WHO position paper. Wkly. Epidemiol. Rec. 80:31-39.
3. Baron, S., E. Njamkepo, E. Grimprel, P. Begue, J. C. Desenclos, J. Drucker,and N. Guiso. 1998. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr. Infect. Dis. J. 17:412-418.
4. Bromberg, K., G. Tannis, and P. Steiner. 1991. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect. Immun. 59:4715-4719.
5. Cohn, S. E., K. L. Knorr, P. H. Gilligan, M. L. Smiley, and D. J. Weber. 1993. Pertussis is rare in human immunodeficiency virus disease. Am. Rev. Respir. Dis. 147:411-413.
6. Doebbeling, B. N., M. L. Feilmeier, and L. A. Herwaldt. 1990. Pertussis in an adult man infected with the human immunodeficiency virus. J. Infect. Dis. 161:1296-1298.
7. Edwards, K. M., and M. D. Decker. 2004. Pertussis vaccine, p. 471-528. In S. A. Plotkin and W. A. Orenstein (ed.), Vaccines, 4th ed. W. B. Saunders Company, Philadelphia, PA.
8. Forsyth, K. D., C. H. Wirsing von Konig, T. Tan, J. Caro, and S. Plotkin. 2007. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 25:2634-2642.
9. Greco, D., S. Salmaso, P. Mastrantonio, M. Giuliano, A. E. Tozzi, A. Anemona, M. L. Ciofi degli Atti, A. Giammanco, P. Panei, W. C. Blackwelder, D. L. Klein, S. G. Wassilak, et al. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-348.
10. Grimprel, E., P. Begue, I. Anjak, E. Njamkepo, P. Francois, and N. Guiso. 1996. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin. Diagn. Lab. Immunol. 3:93-97.
11. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
12. Kretsinger, K., K. R. Broder, M. M. Cortese, M. P. Joyce, I. Ortega-Sanchez, G. M. Lee, T. Tiwari, A. C. Cohn, B. A. Slade, J. K. Iskander, C. M. Mijalski, K. H. Brown, and T. V. Murphy. 2006. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recommend. Rep. 55:1-37.
13. Moss, W. J., C. J. Clements, and N. A. Halsey. 2003. Immunization of children at risk of infection with human immunodeficiency virus. Bull. W. H. o. 81:61-70.
14. Ng, V., L. Weir, M. K. York, and W. K. Hadley. 1992. Bordetella pertussis versus non-L. pneumophila Legionella spp.: a continuing diagnostic challenge. J. Clin. Microbiol. 30:3300-3301.
15. Njamkepo, E., F. Rimlinger, S. Thiberge, and N. Guiso. 2002. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 20:1290-1294.
16. Ramsay, M. E., C. P. Farrington, and E. Miller. 1993. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol. Infect. 111:41-48.
17. Relyveld, E., N. H. Oato, N. Guerin, P. Coursaget, M. Huet, and R. K. Gupta. 1991. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal. Vaccine 9:843-850.
18. Rouet, F., D. K. Ekouevi, M. L. Chaix, M. Burgard, A. Inwoley, T. D. Tony, C. Danel, X. Anglaret, V. Leroy, P. Msellati, F. Dabis, and C. Rouzioux. 2005. Transfer and evaluation of an automated, low-cost real-time reverse tran-scription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43:2709-2717.
19. Simondon, F., I. Iteman, M. P. Preziosi, A. Yam, and N. Guiso. 1998. Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin. Diagn. Lab. Immunol. 5:130-134.
20. Simondon, F., M. P. Preziosi, A. Yam, C. T. Kane, L. Chabirand, I. Iteman, G. Sanden, S. Mboup, A. Hoffenbach, K. Knudsen, N. Guiso, S. Wassilak, and M. Cadoz. 1997. A randomized double-blind trial comparing a twocomponent acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15:1606-1612.
21. Tejiokem, M. C., I. Gouandjika, L. Beniguel, M. C. Zanga, G. Tene, J. C. Gody, E. Njamkepo, A. Kfutwah, I. Penda, C. Bilong, D. Rousset, R. Pouillot, F. Tangy, and L. Baril. 2007. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS oNE 2:e1260.
22. von Konig, C. H., S. Halperin, M. Riffelmann, and N. Guiso. 2002. Pertussis of adults and infants. Lancet Infect. Dis. 2:744-750.
23. Wendelboe, A. M., E. Njamkepo, A. Bourillon, D. D. Floret, J. Gaudelus, M. Gerber, E. Grimprel, D. Greenberg, S. Halperin, J. Liese, F. Munoz-Rivas, R. Teyssou, N. Guiso, and A. Van Rie. 2007. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26:293-299.